nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR1—kidney cancer	0.701	1	CbGaD
Dantrolene—CYP3A4—Everolimus—kidney cancer	0.0398	0.293	CbGbCtD
Dantrolene—CYP3A4—Temsirolimus—kidney cancer	0.0269	0.198	CbGbCtD
Dantrolene—CYP3A4—Pazopanib—kidney cancer	0.0141	0.104	CbGbCtD
Dantrolene—CYP3A4—Erlotinib—kidney cancer	0.0101	0.0741	CbGbCtD
Dantrolene—CYP3A4—Paclitaxel—kidney cancer	0.00923	0.0678	CbGbCtD
Dantrolene—CYP3A4—Sorafenib—kidney cancer	0.0082	0.0603	CbGbCtD
Dantrolene—CYP3A4—Vinblastine—kidney cancer	0.0081	0.0595	CbGbCtD
Dantrolene—CYP3A4—Vincristine—kidney cancer	0.00796	0.0585	CbGbCtD
Dantrolene—CYP3A4—Sunitinib—kidney cancer	0.00665	0.0488	CbGbCtD
Dantrolene—CYP3A4—Doxorubicin—kidney cancer	0.00498	0.0366	CbGbCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—CNN2—kidney cancer	0.00419	0.0895	CbGpPWpGaD
Dantrolene—RYR3—Stimuli-sensing channels—RYR1—kidney cancer	0.00326	0.0696	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—CNN2—kidney cancer	0.00309	0.066	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—RYR1—kidney cancer	0.00227	0.0485	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—RYR1—kidney cancer	0.0022	0.047	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—RYR1—kidney cancer	0.00213	0.0454	CbGpPWpGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—JUN—kidney cancer	0.00194	0.0415	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—MME—kidney cancer	0.00173	0.037	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—APAF1—kidney cancer	0.00161	0.0344	CbGpPWpGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—MAPK1—kidney cancer	0.00153	0.0326	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GJB1—kidney cancer	0.00151	0.0322	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—ITPR2—kidney cancer	0.00146	0.0311	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—CALD1—kidney cancer	0.00132	0.0282	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—ATP7B—kidney cancer	0.00122	0.0261	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GJB1—kidney cancer	0.00111	0.0237	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—CALD1—kidney cancer	0.000973	0.0208	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—ATP7B—kidney cancer	0.0009	0.0192	CbGpPWpGaD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—ITPR2—kidney cancer	0.000878	0.0187	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ITPR2—kidney cancer	0.00085	0.0182	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.00074	0.0158	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00066	0.0141	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—ITPR2—kidney cancer	0.000647	0.0138	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ITPR2—kidney cancer	0.000627	0.0134	CbGpPWpGaD
Dantrolene—RYR3—Stimuli-sensing channels—RAF1—kidney cancer	0.000426	0.00909	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000425	0.00907	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000425	0.00907	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000425	0.00907	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000415	0.00885	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—MAPK3—kidney cancer	0.000356	0.0076	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—MAPK1—kidney cancer	0.000338	0.00723	CbGpPWpGaD
Dantrolene—RYR1—Stimuli-sensing channels—RAF1—kidney cancer	0.000314	0.0067	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000313	0.00669	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000313	0.00669	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000313	0.00669	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000301	0.00642	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—TP53—kidney cancer	0.000284	0.00607	CbGpPWpGaD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000278	0.00594	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—RAF1—kidney cancer	0.000278	0.00593	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—JUN—kidney cancer	0.000251	0.00536	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000236	0.00504	CbGpPWpGaD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.000233	0.00498	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000224	0.00479	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000216	0.00462	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—RAF1—kidney cancer	0.000205	0.00437	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—JUN—kidney cancer	0.000185	0.00395	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000178	0.0038	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000171	0.00365	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000165	0.00353	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.00016	0.00341	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000152	0.00325	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000147	0.00314	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000141	0.00302	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000134	0.00286	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000128	0.00274	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000126	0.00269	CbGpPWpGaD
Dantrolene—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000123	0.00263	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000118	0.00253	CbGpPWpGaD
Dantrolene—Decreased appetite—Dactinomycin—kidney cancer	0.000118	0.00102	CcSEcCtD
Dantrolene—Diarrhoea—Vinblastine—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Abdominal pain—Sorafenib—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Body temperature increased—Sorafenib—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Diarrhoea—Everolimus—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Gastrointestinal pain—Sunitinib—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Hyperhidrosis—Vincristine—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000117	0.00249	CbGpPWpGaD
Dantrolene—Pruritus—Erlotinib—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Fatigue—Dactinomycin—kidney cancer	0.000117	0.00101	CcSEcCtD
Dantrolene—Pain—Dactinomycin—kidney cancer	0.000116	0.000999	CcSEcCtD
Dantrolene—Tension—Paclitaxel—kidney cancer	0.000115	0.000997	CcSEcCtD
Dantrolene—Anorexia—Vincristine—kidney cancer	0.000115	0.000995	CcSEcCtD
Dantrolene—Dysgeusia—Paclitaxel—kidney cancer	0.000115	0.000995	CcSEcCtD
Dantrolene—Hepatic failure—Doxorubicin—kidney cancer	0.000115	0.000993	CcSEcCtD
Dantrolene—Anaphylactic shock—Gemcitabine—kidney cancer	0.000115	0.00099	CcSEcCtD
Dantrolene—Nervousness—Paclitaxel—kidney cancer	0.000114	0.000987	CcSEcCtD
Dantrolene—Back pain—Paclitaxel—kidney cancer	0.000114	0.000983	CcSEcCtD
Dantrolene—Dizziness—Vinblastine—kidney cancer	0.000114	0.000981	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000113	0.00242	CbGpPWpGaD
Dantrolene—Dizziness—Everolimus—kidney cancer	0.000113	0.000977	CcSEcCtD
Dantrolene—Abdominal pain—Sunitinib—kidney cancer	0.000113	0.000976	CcSEcCtD
Dantrolene—Body temperature increased—Sunitinib—kidney cancer	0.000113	0.000976	CcSEcCtD
Dantrolene—Diarrhoea—Erlotinib—kidney cancer	0.000113	0.000975	CcSEcCtD
Dantrolene—Thrombocytopenia—Gemcitabine—kidney cancer	0.000112	0.00097	CcSEcCtD
Dantrolene—Feeling abnormal—Dactinomycin—kidney cancer	0.000111	0.000963	CcSEcCtD
Dantrolene—Haemoglobin—Capecitabine—kidney cancer	0.000111	0.000963	CcSEcCtD
Dantrolene—Haemorrhage—Capecitabine—kidney cancer	0.000111	0.000958	CcSEcCtD
Dantrolene—Hepatitis—Capecitabine—kidney cancer	0.000111	0.000958	CcSEcCtD
Dantrolene—Vision blurred—Paclitaxel—kidney cancer	0.000111	0.000957	CcSEcCtD
Dantrolene—Hyperhidrosis—Gemcitabine—kidney cancer	0.000111	0.000957	CcSEcCtD
Dantrolene—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000111	0.000955	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00011	0.000951	CcSEcCtD
Dantrolene—Hypersensitivity—Sorafenib—kidney cancer	0.000109	0.000945	CcSEcCtD
Dantrolene—Insomnia—Vincristine—kidney cancer	0.000109	0.000944	CcSEcCtD
Dantrolene—Anorexia—Gemcitabine—kidney cancer	0.000109	0.000944	CcSEcCtD
Dantrolene—Vomiting—Vinblastine—kidney cancer	0.000109	0.000943	CcSEcCtD
Dantrolene—Dizziness—Erlotinib—kidney cancer	0.000109	0.000943	CcSEcCtD
Dantrolene—Ill-defined disorder—Paclitaxel—kidney cancer	0.000109	0.000943	CcSEcCtD
Dantrolene—Vomiting—Everolimus—kidney cancer	0.000109	0.000939	CcSEcCtD
Dantrolene—Anaemia—Paclitaxel—kidney cancer	0.000109	0.000939	CcSEcCtD
Dantrolene—Rash—Everolimus—kidney cancer	0.000108	0.000932	CcSEcCtD
Dantrolene—Dermatitis—Everolimus—kidney cancer	0.000108	0.000931	CcSEcCtD
Dantrolene—Headache—Vinblastine—kidney cancer	0.000108	0.000929	CcSEcCtD
Dantrolene—Headache—Everolimus—kidney cancer	0.000107	0.000926	CcSEcCtD
Dantrolene—Abdominal pain—Dactinomycin—kidney cancer	0.000107	0.000924	CcSEcCtD
Dantrolene—Body temperature increased—Dactinomycin—kidney cancer	0.000107	0.000924	CcSEcCtD
Dantrolene—Visual impairment—Capecitabine—kidney cancer	0.000107	0.000923	CcSEcCtD
Dantrolene—Asthenia—Sorafenib—kidney cancer	0.000107	0.00092	CcSEcCtD
Dantrolene—Malaise—Paclitaxel—kidney cancer	0.000106	0.000916	CcSEcCtD
Dantrolene—Cardiac failure—Doxorubicin—kidney cancer	0.000106	0.000914	CcSEcCtD
Dantrolene—Leukopenia—Paclitaxel—kidney cancer	0.000105	0.000909	CcSEcCtD
Dantrolene—Hypersensitivity—Sunitinib—kidney cancer	0.000105	0.000909	CcSEcCtD
Dantrolene—Decreased appetite—Vincristine—kidney cancer	0.000105	0.000907	CcSEcCtD
Dantrolene—Pruritus—Sorafenib—kidney cancer	0.000105	0.000907	CcSEcCtD
Dantrolene—Vomiting—Erlotinib—kidney cancer	0.000105	0.000906	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000104	0.000902	CcSEcCtD
Dantrolene—Fatigue—Vincristine—kidney cancer	0.000104	0.0009	CcSEcCtD
Dantrolene—Rash—Erlotinib—kidney cancer	0.000104	0.000899	CcSEcCtD
Dantrolene—Dermatitis—Erlotinib—kidney cancer	0.000104	0.000898	CcSEcCtD
Dantrolene—Insomnia—Gemcitabine—kidney cancer	0.000104	0.000896	CcSEcCtD
Dantrolene—Headache—Erlotinib—kidney cancer	0.000103	0.000893	CcSEcCtD
Dantrolene—Pain—Vincristine—kidney cancer	0.000103	0.000893	CcSEcCtD
Dantrolene—Constipation—Vincristine—kidney cancer	0.000103	0.000893	CcSEcCtD
Dantrolene—Diplopia—Doxorubicin—kidney cancer	0.000103	0.000892	CcSEcCtD
Dantrolene—Pain in extremity—Doxorubicin—kidney cancer	0.000103	0.000892	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000103	0.000892	CcSEcCtD
Dantrolene—Flushing—Capecitabine—kidney cancer	0.000103	0.000889	CcSEcCtD
Dantrolene—Asthenia—Sunitinib—kidney cancer	0.000102	0.000885	CcSEcCtD
Dantrolene—Nausea—Vinblastine—kidney cancer	0.000102	0.000881	CcSEcCtD
Dantrolene—Somnolence—Gemcitabine—kidney cancer	0.000102	0.00088	CcSEcCtD
Dantrolene—Convulsion—Paclitaxel—kidney cancer	0.000102	0.00088	CcSEcCtD
Dantrolene—Nausea—Everolimus—kidney cancer	0.000102	0.000878	CcSEcCtD
Dantrolene—Diarrhoea—Sorafenib—kidney cancer	0.000102	0.000878	CcSEcCtD
Dantrolene—Hypertension—Paclitaxel—kidney cancer	0.000102	0.000877	CcSEcCtD
Dantrolene—Pruritus—Sunitinib—kidney cancer	0.000101	0.000873	CcSEcCtD
Dantrolene—Myalgia—Paclitaxel—kidney cancer	0.0001	0.000865	CcSEcCtD
Dantrolene—Decreased appetite—Gemcitabine—kidney cancer	9.96e-05	0.000861	CcSEcCtD
Dantrolene—Hypersensitivity—Dactinomycin—kidney cancer	9.96e-05	0.000861	CcSEcCtD
Dantrolene—Chills—Capecitabine—kidney cancer	9.95e-05	0.000859	CcSEcCtD
Dantrolene—Discomfort—Paclitaxel—kidney cancer	9.89e-05	0.000855	CcSEcCtD
Dantrolene—Fatigue—Gemcitabine—kidney cancer	9.88e-05	0.000854	CcSEcCtD
Dantrolene—Gastrointestinal pain—Vincristine—kidney cancer	9.88e-05	0.000854	CcSEcCtD
Dantrolene—Dizziness—Sorafenib—kidney cancer	9.82e-05	0.000848	CcSEcCtD
Dantrolene—Constipation—Gemcitabine—kidney cancer	9.8e-05	0.000847	CcSEcCtD
Dantrolene—Pain—Gemcitabine—kidney cancer	9.8e-05	0.000847	CcSEcCtD
Dantrolene—Nausea—Erlotinib—kidney cancer	9.8e-05	0.000847	CcSEcCtD
Dantrolene—Dry mouth—Paclitaxel—kidney cancer	9.79e-05	0.000846	CcSEcCtD
Dantrolene—Diarrhoea—Sunitinib—kidney cancer	9.77e-05	0.000844	CcSEcCtD
Dantrolene—Asthenia—Dactinomycin—kidney cancer	9.7e-05	0.000838	CcSEcCtD
Dantrolene—Confusional state—Paclitaxel—kidney cancer	9.68e-05	0.000836	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—RAF1—kidney cancer	9.67e-05	0.00206	CbGpPWpGaD
Dantrolene—Erythema—Capecitabine—kidney cancer	9.65e-05	0.000834	CcSEcCtD
Dantrolene—Anaphylactic shock—Paclitaxel—kidney cancer	9.6e-05	0.000829	CcSEcCtD
Dantrolene—Body temperature increased—Vincristine—kidney cancer	9.55e-05	0.000825	CcSEcCtD
Dantrolene—Abdominal pain—Vincristine—kidney cancer	9.55e-05	0.000825	CcSEcCtD
Dantrolene—Dysgeusia—Capecitabine—kidney cancer	9.45e-05	0.000816	CcSEcCtD
Dantrolene—Dizziness—Sunitinib—kidney cancer	9.45e-05	0.000816	CcSEcCtD
Dantrolene—Feeling abnormal—Gemcitabine—kidney cancer	9.44e-05	0.000816	CcSEcCtD
Dantrolene—Vomiting—Sorafenib—kidney cancer	9.44e-05	0.000815	CcSEcCtD
Dantrolene—Thrombocytopenia—Paclitaxel—kidney cancer	9.4e-05	0.000812	CcSEcCtD
Dantrolene—Tachycardia—Paclitaxel—kidney cancer	9.37e-05	0.000809	CcSEcCtD
Dantrolene—Rash—Sorafenib—kidney cancer	9.36e-05	0.000809	CcSEcCtD
Dantrolene—Dermatitis—Sorafenib—kidney cancer	9.35e-05	0.000808	CcSEcCtD
Dantrolene—Back pain—Capecitabine—kidney cancer	9.33e-05	0.000806	CcSEcCtD
Dantrolene—Headache—Sorafenib—kidney cancer	9.3e-05	0.000803	CcSEcCtD
Dantrolene—Hyperhidrosis—Paclitaxel—kidney cancer	9.28e-05	0.000802	CcSEcCtD
Dantrolene—Diarrhoea—Dactinomycin—kidney cancer	9.25e-05	0.000799	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	9.18e-05	0.00196	CbGpPWpGaD
Dantrolene—Anorexia—Paclitaxel—kidney cancer	9.15e-05	0.00079	CcSEcCtD
Dantrolene—Muscular weakness—Doxorubicin—kidney cancer	9.11e-05	0.000787	CcSEcCtD
Dantrolene—Vision blurred—Capecitabine—kidney cancer	9.09e-05	0.000786	CcSEcCtD
Dantrolene—Vomiting—Sunitinib—kidney cancer	9.08e-05	0.000785	CcSEcCtD
Dantrolene—Body temperature increased—Gemcitabine—kidney cancer	9.06e-05	0.000783	CcSEcCtD
Dantrolene—Rash—Sunitinib—kidney cancer	9.01e-05	0.000778	CcSEcCtD
Dantrolene—Dermatitis—Sunitinib—kidney cancer	9e-05	0.000777	CcSEcCtD
Dantrolene—Ill-defined disorder—Capecitabine—kidney cancer	8.95e-05	0.000774	CcSEcCtD
Dantrolene—Headache—Sunitinib—kidney cancer	8.95e-05	0.000773	CcSEcCtD
Dantrolene—Dysphagia—Doxorubicin—kidney cancer	8.93e-05	0.000771	CcSEcCtD
Dantrolene—Anaemia—Capecitabine—kidney cancer	8.92e-05	0.000771	CcSEcCtD
Dantrolene—Hypersensitivity—Vincristine—kidney cancer	8.9e-05	0.000769	CcSEcCtD
Dantrolene—Eosinophilia—Doxorubicin—kidney cancer	8.84e-05	0.000764	CcSEcCtD
Dantrolene—Nausea—Sorafenib—kidney cancer	8.82e-05	0.000762	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	8.75e-05	0.00187	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Paclitaxel—kidney cancer	8.74e-05	0.000755	CcSEcCtD
Dantrolene—Malaise—Capecitabine—kidney cancer	8.7e-05	0.000752	CcSEcCtD
Dantrolene—Insomnia—Paclitaxel—kidney cancer	8.68e-05	0.00075	CcSEcCtD
Dantrolene—Asthenia—Vincristine—kidney cancer	8.67e-05	0.000749	CcSEcCtD
Dantrolene—Leukopenia—Capecitabine—kidney cancer	8.64e-05	0.000746	CcSEcCtD
Dantrolene—Vomiting—Dactinomycin—kidney cancer	8.6e-05	0.000743	CcSEcCtD
Dantrolene—Somnolence—Paclitaxel—kidney cancer	8.53e-05	0.000737	CcSEcCtD
Dantrolene—Rash—Dactinomycin—kidney cancer	8.53e-05	0.000737	CcSEcCtD
Dantrolene—Nausea—Sunitinib—kidney cancer	8.48e-05	0.000733	CcSEcCtD
Dantrolene—Dyspepsia—Paclitaxel—kidney cancer	8.45e-05	0.00073	CcSEcCtD
Dantrolene—Decreased appetite—Paclitaxel—kidney cancer	8.34e-05	0.000721	CcSEcCtD
Dantrolene—Hypertension—Capecitabine—kidney cancer	8.33e-05	0.00072	CcSEcCtD
Dantrolene—Fatigue—Paclitaxel—kidney cancer	8.27e-05	0.000715	CcSEcCtD
Dantrolene—Diarrhoea—Vincristine—kidney cancer	8.27e-05	0.000714	CcSEcCtD
Dantrolene—Pollakiuria—Doxorubicin—kidney cancer	8.25e-05	0.000712	CcSEcCtD
Dantrolene—Asthenia—Gemcitabine—kidney cancer	8.22e-05	0.00071	CcSEcCtD
Dantrolene—Myalgia—Capecitabine—kidney cancer	8.21e-05	0.00071	CcSEcCtD
Dantrolene—Pain—Paclitaxel—kidney cancer	8.21e-05	0.000709	CcSEcCtD
Dantrolene—Constipation—Paclitaxel—kidney cancer	8.21e-05	0.000709	CcSEcCtD
Dantrolene—Discomfort—Capecitabine—kidney cancer	8.12e-05	0.000701	CcSEcCtD
Dantrolene—Pruritus—Gemcitabine—kidney cancer	8.11e-05	0.000701	CcSEcCtD
Dantrolene—Dry mouth—Capecitabine—kidney cancer	8.03e-05	0.000694	CcSEcCtD
Dantrolene—Nausea—Dactinomycin—kidney cancer	8.03e-05	0.000694	CcSEcCtD
Dantrolene—Dizziness—Vincristine—kidney cancer	7.99e-05	0.00069	CcSEcCtD
Dantrolene—Drowsiness—Doxorubicin—kidney cancer	7.96e-05	0.000688	CcSEcCtD
Dantrolene—Confusional state—Capecitabine—kidney cancer	7.94e-05	0.000686	CcSEcCtD
Dantrolene—Feeling abnormal—Paclitaxel—kidney cancer	7.91e-05	0.000683	CcSEcCtD
Dantrolene—Gastrointestinal pain—Paclitaxel—kidney cancer	7.85e-05	0.000678	CcSEcCtD
Dantrolene—Diarrhoea—Gemcitabine—kidney cancer	7.84e-05	0.000678	CcSEcCtD
Dantrolene—Renal failure—Doxorubicin—kidney cancer	7.82e-05	0.000676	CcSEcCtD
Dantrolene—Thrombocytopenia—Capecitabine—kidney cancer	7.71e-05	0.000666	CcSEcCtD
Dantrolene—Tachycardia—Capecitabine—kidney cancer	7.69e-05	0.000664	CcSEcCtD
Dantrolene—Vomiting—Vincristine—kidney cancer	7.68e-05	0.000664	CcSEcCtD
Dantrolene—Sweating—Doxorubicin—kidney cancer	7.63e-05	0.000659	CcSEcCtD
Dantrolene—Urticaria—Paclitaxel—kidney cancer	7.62e-05	0.000659	CcSEcCtD
Dantrolene—Rash—Vincristine—kidney cancer	7.62e-05	0.000658	CcSEcCtD
Dantrolene—Hyperhidrosis—Capecitabine—kidney cancer	7.61e-05	0.000658	CcSEcCtD
Dantrolene—Dermatitis—Vincristine—kidney cancer	7.61e-05	0.000658	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—kidney cancer	7.59e-05	0.000656	CcSEcCtD
Dantrolene—Body temperature increased—Paclitaxel—kidney cancer	7.59e-05	0.000655	CcSEcCtD
Dantrolene—Abdominal pain—Paclitaxel—kidney cancer	7.59e-05	0.000655	CcSEcCtD
Dantrolene—Headache—Vincristine—kidney cancer	7.57e-05	0.000654	CcSEcCtD
Dantrolene—Anorexia—Capecitabine—kidney cancer	7.51e-05	0.000649	CcSEcCtD
Dantrolene—Vomiting—Gemcitabine—kidney cancer	7.29e-05	0.00063	CcSEcCtD
Dantrolene—Rash—Gemcitabine—kidney cancer	7.23e-05	0.000624	CcSEcCtD
Dantrolene—Dermatitis—Gemcitabine—kidney cancer	7.22e-05	0.000624	CcSEcCtD
Dantrolene—Haemoglobin—Doxorubicin—kidney cancer	7.18e-05	0.00062	CcSEcCtD
Dantrolene—Headache—Gemcitabine—kidney cancer	7.18e-05	0.00062	CcSEcCtD
Dantrolene—Nausea—Vincristine—kidney cancer	7.18e-05	0.00062	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Capecitabine—kidney cancer	7.17e-05	0.00062	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—kidney cancer	7.14e-05	0.000617	CcSEcCtD
Dantrolene—Hepatitis—Doxorubicin—kidney cancer	7.14e-05	0.000617	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.13e-05	0.00152	CbGpPWpGaD
Dantrolene—Insomnia—Capecitabine—kidney cancer	7.12e-05	0.000615	CcSEcCtD
Dantrolene—Hypersensitivity—Paclitaxel—kidney cancer	7.07e-05	0.000611	CcSEcCtD
Dantrolene—Dyspepsia—Capecitabine—kidney cancer	6.93e-05	0.000599	CcSEcCtD
Dantrolene—Visual impairment—Doxorubicin—kidney cancer	6.89e-05	0.000595	CcSEcCtD
Dantrolene—Asthenia—Paclitaxel—kidney cancer	6.88e-05	0.000595	CcSEcCtD
Dantrolene—Decreased appetite—Capecitabine—kidney cancer	6.85e-05	0.000591	CcSEcCtD
Dantrolene—Nausea—Gemcitabine—kidney cancer	6.81e-05	0.000588	CcSEcCtD
Dantrolene—Fatigue—Capecitabine—kidney cancer	6.79e-05	0.000587	CcSEcCtD
Dantrolene—Pruritus—Paclitaxel—kidney cancer	6.79e-05	0.000587	CcSEcCtD
Dantrolene—Pain—Capecitabine—kidney cancer	6.73e-05	0.000582	CcSEcCtD
Dantrolene—Constipation—Capecitabine—kidney cancer	6.73e-05	0.000582	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—kidney cancer	6.63e-05	0.000573	CcSEcCtD
Dantrolene—Diarrhoea—Paclitaxel—kidney cancer	6.57e-05	0.000567	CcSEcCtD
Dantrolene—Feeling abnormal—Capecitabine—kidney cancer	6.49e-05	0.000561	CcSEcCtD
Dantrolene—Gastrointestinal pain—Capecitabine—kidney cancer	6.44e-05	0.000556	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	6.43e-05	0.00137	CbGpPWpGaD
Dantrolene—Chills—Doxorubicin—kidney cancer	6.41e-05	0.000554	CcSEcCtD
Dantrolene—Dizziness—Paclitaxel—kidney cancer	6.35e-05	0.000548	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	6.32e-05	0.00135	CbGpPWpGaD
Dantrolene—Urticaria—Capecitabine—kidney cancer	6.26e-05	0.000541	CcSEcCtD
Dantrolene—Abdominal pain—Capecitabine—kidney cancer	6.23e-05	0.000538	CcSEcCtD
Dantrolene—Body temperature increased—Capecitabine—kidney cancer	6.23e-05	0.000538	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—kidney cancer	6.22e-05	0.000537	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	6.2e-05	0.00132	CbGpPWpGaD
Dantrolene—Tension—Doxorubicin—kidney cancer	6.1e-05	0.000527	CcSEcCtD
Dantrolene—Vomiting—Paclitaxel—kidney cancer	6.1e-05	0.000527	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—kidney cancer	6.09e-05	0.000526	CcSEcCtD
Dantrolene—Rash—Paclitaxel—kidney cancer	6.05e-05	0.000523	CcSEcCtD
Dantrolene—Dermatitis—Paclitaxel—kidney cancer	6.04e-05	0.000522	CcSEcCtD
Dantrolene—Nervousness—Doxorubicin—kidney cancer	6.04e-05	0.000522	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—kidney cancer	6.02e-05	0.00052	CcSEcCtD
Dantrolene—Headache—Paclitaxel—kidney cancer	6.01e-05	0.000519	CcSEcCtD
Dantrolene—Vision blurred—Doxorubicin—kidney cancer	5.86e-05	0.000506	CcSEcCtD
Dantrolene—Hypersensitivity—Capecitabine—kidney cancer	5.8e-05	0.000501	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—kidney cancer	5.77e-05	0.000499	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—kidney cancer	5.75e-05	0.000497	CcSEcCtD
Dantrolene—Nausea—Paclitaxel—kidney cancer	5.7e-05	0.000492	CcSEcCtD
Dantrolene—Asthenia—Capecitabine—kidney cancer	5.65e-05	0.000488	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—kidney cancer	5.61e-05	0.000485	CcSEcCtD
Dantrolene—Pruritus—Capecitabine—kidney cancer	5.57e-05	0.000481	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—kidney cancer	5.57e-05	0.000481	CcSEcCtD
Dantrolene—Convulsion—Doxorubicin—kidney cancer	5.39e-05	0.000466	CcSEcCtD
Dantrolene—Diarrhoea—Capecitabine—kidney cancer	5.39e-05	0.000466	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—kidney cancer	5.37e-05	0.000464	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—kidney cancer	5.3e-05	0.000458	CcSEcCtD
Dantrolene—Discomfort—Doxorubicin—kidney cancer	5.23e-05	0.000452	CcSEcCtD
Dantrolene—Dizziness—Capecitabine—kidney cancer	5.21e-05	0.00045	CcSEcCtD
Dantrolene—Dry mouth—Doxorubicin—kidney cancer	5.18e-05	0.000447	CcSEcCtD
Dantrolene—Confusional state—Doxorubicin—kidney cancer	5.12e-05	0.000442	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	5.11e-05	0.00109	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Doxorubicin—kidney cancer	5.08e-05	0.000439	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	5.04e-05	0.00108	CbGpPWpGaD
Dantrolene—Vomiting—Capecitabine—kidney cancer	5.01e-05	0.000433	CcSEcCtD
Dantrolene—Thrombocytopenia—Doxorubicin—kidney cancer	4.97e-05	0.000429	CcSEcCtD
Dantrolene—Rash—Capecitabine—kidney cancer	4.97e-05	0.000429	CcSEcCtD
Dantrolene—Dermatitis—Capecitabine—kidney cancer	4.96e-05	0.000429	CcSEcCtD
Dantrolene—Tachycardia—Doxorubicin—kidney cancer	4.95e-05	0.000428	CcSEcCtD
Dantrolene—Headache—Capecitabine—kidney cancer	4.93e-05	0.000426	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—kidney cancer	4.91e-05	0.000424	CcSEcCtD
Dantrolene—Anorexia—Doxorubicin—kidney cancer	4.84e-05	0.000418	CcSEcCtD
Dantrolene—Nausea—Capecitabine—kidney cancer	4.68e-05	0.000404	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—kidney cancer	4.62e-05	0.0004	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—kidney cancer	4.59e-05	0.000397	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—kidney cancer	4.51e-05	0.00039	CcSEcCtD
Dantrolene—Dyspepsia—Doxorubicin—kidney cancer	4.47e-05	0.000386	CcSEcCtD
Dantrolene—Decreased appetite—Doxorubicin—kidney cancer	4.41e-05	0.000381	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—kidney cancer	4.38e-05	0.000378	CcSEcCtD
Dantrolene—Pain—Doxorubicin—kidney cancer	4.34e-05	0.000375	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—kidney cancer	4.34e-05	0.000375	CcSEcCtD
Dantrolene—Feeling abnormal—Doxorubicin—kidney cancer	4.18e-05	0.000361	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—kidney cancer	4.15e-05	0.000359	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	4.14e-05	0.000885	CbGpPWpGaD
Dantrolene—Urticaria—Doxorubicin—kidney cancer	4.03e-05	0.000348	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—kidney cancer	4.01e-05	0.000347	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—kidney cancer	4.01e-05	0.000347	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.81e-05	0.000814	CbGpPWpGaD
Dantrolene—Hypersensitivity—Doxorubicin—kidney cancer	3.74e-05	0.000323	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTT1—kidney cancer	3.64e-05	0.000778	CbGpPWpGaD
Dantrolene—Asthenia—Doxorubicin—kidney cancer	3.64e-05	0.000315	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—kidney cancer	3.59e-05	0.00031	CcSEcCtD
Dantrolene—Diarrhoea—Doxorubicin—kidney cancer	3.47e-05	0.0003	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—PTGS1—kidney cancer	3.42e-05	0.000729	CbGpPWpGaD
Dantrolene—Dizziness—Doxorubicin—kidney cancer	3.36e-05	0.00029	CcSEcCtD
Dantrolene—Vomiting—Doxorubicin—kidney cancer	3.23e-05	0.000279	CcSEcCtD
Dantrolene—Rash—Doxorubicin—kidney cancer	3.2e-05	0.000277	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—kidney cancer	3.2e-05	0.000276	CcSEcCtD
Dantrolene—Headache—Doxorubicin—kidney cancer	3.18e-05	0.000275	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.09e-05	0.00066	CbGpPWpGaD
Dantrolene—Nausea—Doxorubicin—kidney cancer	3.02e-05	0.000261	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.53e-05	0.000539	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.49e-05	0.000532	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.32e-05	0.000496	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.29e-05	0.000489	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.2e-05	0.00047	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.17e-05	0.000463	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACY1—kidney cancer	1.94e-05	0.000413	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PDHB—kidney cancer	1.65e-05	0.000351	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—POMC—kidney cancer	1.64e-05	0.00035	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CCBL1—kidney cancer	1.55e-05	0.00033	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPAT—kidney cancer	1.34e-05	0.000286	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.34e-05	0.000286	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—APRT—kidney cancer	1.25e-05	0.000266	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—FH—kidney cancer	1.25e-05	0.000266	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPC3—kidney cancer	1.17e-05	0.00025	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CA2—kidney cancer	1.14e-05	0.000244	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALAD—kidney cancer	1.11e-05	0.000237	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.09e-05	0.000232	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.06e-05	0.000226	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PGK1—kidney cancer	1.02e-05	0.000217	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.02e-05	0.000217	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LDHB—kidney cancer	9.97e-06	0.000213	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CA9—kidney cancer	8.65e-06	0.000185	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CRABP1—kidney cancer	7.35e-06	0.000157	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ITPR2—kidney cancer	6.83e-06	0.000146	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACHE—kidney cancer	6.23e-06	0.000133	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTT1—kidney cancer	6.23e-06	0.000133	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SCARB1—kidney cancer	5.9e-06	0.000126	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS1—kidney cancer	5.84e-06	0.000125	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSMD7—kidney cancer	5.73e-06	0.000122	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BCHE—kidney cancer	5.43e-06	0.000116	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.36e-06	0.000115	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.18e-06	0.000111	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—kidney cancer	4.32e-06	9.22e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCB1—kidney cancer	4.09e-06	8.73e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—kidney cancer	3.97e-06	8.48e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.76e-06	8.04e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—POMC—kidney cancer	2.81e-06	5.99e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—kidney cancer	2.24e-06	4.78e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTEN—kidney cancer	1.95e-06	4.17e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.38e-06	2.94e-05	CbGpPWpGaD
